Loxo Oncology has earned considerable buzz and a hefty stock market valuation for bringing a genomic-based approach to cancer drug development. The Connecticut biotech’s drugs target highly specific genetic mutations found in cancer cells, regardless of where in the body the tumor is located.
The first of Loxo’s experimental drugs, larotrectinib, has already demonstrated a strong cancer-killing ability in tumors with a genetic alteration called a TRK gene fusion. The drug is under FDA review with an approval decision expected in late November.
On Saturday, Loxo is unveiling clinical trial data for the first time showing a second drug, LOXO-292, is equally capable of eliminating tumors containing a mutated protein known as RET.
About the Author Reprints
